2 results
Approved WMOPending
To investigate the long-term safety, tolerability and acceptability of Nasalfent in the treatment BTCP
Approved WMOCompleted
• To estimate the difference in the efficacy and safety of RAD001 10 mg p.o. daily dose in combination with bevacizumab 10 mg/kg administered intravenously every two weeks for first-line treatment of patients with metastatic carcinoma of the kidney…